Jul 31, 2012
By:
Jennifer Markarian
Pharmaceutical industry leaders Pfizer, Novartis, and Merck—among others—released second-quarter 2012 results, emphasizing growth of new products and strength in emerging markets.
|
Jul 16, 2012
By:
Jennifer Markarian
Global spending on medicines is estimated to reach nearly $1.2 trillion by 2016.
|
Jun 25, 2012
By:
Jennifer Markarian
US court ruled in favor of Teva in its patent-infringement lawsuit against Momenta and Mylan's generic versions of Teva's Copaxone.
|
Jun 11, 2012
By:
Jennifer Markarian
European and US associations call for continued vigilance against the threat of counterfeit medicines.
|
May 21, 2012
By:
Jennifer Markarian
Human Genome Sciences rejects GlaxoSmithKline offer to acquire the company and issues a poison pill to prevent a takeover.
|
Mar 20, 2012
By:
Jennifer Markarian
On Mar. 12, 2012, FDA released a draft guidance document for industry direct-to-consumer (DTC) television advertisements that describes FDA?s plans for implementing predissemination review.
|
Feb 3, 2012
By:
Jennifer Markarian
Pfizer announced a decrease in fourth-quarter revenues, but a slight increase in full-year 2011 revenues in its financial report issued on Jan. 31, 2012. Ian Read, chairman and CEO, stated in a company release, ?Overall, 2011 was a year of setting new direction and focus for Pfizer. I am pleased with our 2011 financial performance, which was achieved in the face of a challenging global market and product losses of exclusivity of approximately $5 billion.?
|
|
